This long standing RO1 explores epigenetic abnormalities underlying the evolution of colorectal cancer (CRC). We have defined the presence and significance of the many genes that evolve promoter, CpG island, DNA hypermethylation, and associated gene silencing in CRC. During the present funding cycle, we have integrally linked these above events with environmental stresses underlying the earliest steps in CRC tumorigenesis. In this competitive renewal, we take this paradigm forward by tying epigenetic events to the CRC risk state of chronic inflammation, and how it interacts with key genetic alterations to drive the evolution of CRC, the third most common cause of cancer deaths in the US (U.S. Cancer Statistics Working Group). Specifically, we have observed that exposure to reactive oxygen species (ROS) can rapidly induce the targeting, to CpG rich gene promoter regions, of protein complexes which can initiate gene promoter, DNA hypermethylation. These complexes contain not only DNA methyltransferases (DNMT's), the enzymes which catalyze DNA methylation, but also other transcriptional repression proteins which key candidates for initiating, and maintaining, DNA hypermethylation and attendant gene silencing. Among the proteins involved are the polycomb silencing group (PcG) and SIRT1, both players in DNA damage responses, and from our recent data, the NURD complex, transcriptionally repressive chromatin remodeling complex. Finally, we show in a mouse knockout model how HIC-1, a gene which is not mutated, but frequently epigenetically silenced in human CRC, can help drive early events in colon tumorigenesis. We have defined how loss of function of this gene, which encodes a transcriptional repression factor important in development, causes key stem compartment alterations in the intestine, and includes among its repression targets,SIRT1. We now explore further, using in-vivo and in-vitro models, how the protein complexes above initiate and maintain inflammation induced gene silencing, including for HIC1, and how these epigenetic abnormalities work with genetic alterations to foster CRC risk/initiation. The studies in this proposal provide insights for understanding how environmental risk factors underlie CRC risk/initiation and define molecular steps which are candidate targets for preventing CRC.

Public Health Relevance

A common event in the early risk/initiation stages of colorectal cancer (CRC) is abnormal, promoter, CpG island, DNA hypermethylation and associated epigenetic gene silencing. We investigate the molecular mechanisms though which this arises and how it fosters CRC risk and initiation.

National Institute of Health (NIH)
National Institute of Environmental Health Sciences (NIEHS)
Research Project (R01)
Project #
Application #
Study Section
Cancer Molecular Pathobiology Study Section (CAMP)
Program Officer
Tyson, Frederick L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Xia, Limin; Huang, Wenjie; Bellani, Marina et al. (2017) CHD4 Has Oncogenic Functions in Initiating and Maintaining Epigenetic Suppression of Multiple Tumor Suppressor Genes. Cancer Cell 31:653-668.e7
Vaz, Michelle; Hwang, Stephen Y; Kagiampakis, Ioannis et al. (2017) Chronic Cigarette Smoke-Induced Epigenomic Changes Precede Sensitization of Bronchial Epithelial Cells to Single-Step Transformation by KRAS Mutations. Cancer Cell 32:360-376.e6
Zhang, Yang W; Wang, Zhihong; Xie, Wenbing et al. (2017) Acetylation Enhances TET2 Function in Protecting against Abnormal DNA Methylation during Oxidative Stress. Mol Cell 65:323-335
Cai, Yi; Tsai, Hsing-Chen; Yen, Ray-Whay Chiu et al. (2017) Critical threshold levels of DNA methyltransferase 1 are required to maintain DNA methylation across the genome in human cancer cells. Genome Res 27:533-544
Ding, Ning; Bonham, Emily M; Hannon, Brooke E et al. (2016) Mismatch repair proteins recruit DNA methyltransferase 1 to sites of oxidative DNA damage. J Mol Cell Biol 8:244-54
Ahuja, Nita; Sharma, Anup R; Baylin, Stephen B (2016) Epigenetic Therapeutics: A New Weapon in the War Against Cancer. Annu Rev Med 67:73-89
Easwaran, Hariharan; Tsai, Hsing-Chen; Baylin, Stephen B (2014) Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell 54:716-27
Ahuja, Nita; Easwaran, Hariharan; Baylin, Stephen B (2014) Harnessing the potential of epigenetic therapy to target solid tumors. J Clin Invest 124:56-63
Cai, Y; Geutjes, E-J; de Lint, K et al. (2014) The NuRD complex cooperates with DNMTs to maintain silencing of key colorectal tumor suppressor genes. Oncogene 33:2157-68
Cui, Ying; Hausheer, Frederick; Beaty, Robert et al. (2014) A recombinant reporter system for monitoring reactivation of an endogenously DNA hypermethylated gene. Cancer Res 74:3834-43

Showing the most recent 10 out of 40 publications